12.11.2024  17:19:00 Zm. -3,70 Wolumen Bid- Ask- Kapitalizacja Rynkowa St. dywidendy Wskaźnik C/Z
262,30CHF -1,39% 13 927
Obrót: 3,66 mln
-Wolumen Bid: - -Wolumen Ask: - 242,58 mldCHF 3,66% 18,22

Opis działalności

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
 

Zarząd & Rada nadzorcza

CEO
Dr. Thomas Schinecker
Zarząd
Dr. Alan Hippe, Cristina A. Wilbur, Teresa Graham, Matt Sause , Claudia Bockstiegel, Prof. Dr. Hans Clevers, Dr. Levi Garraway, Silke Hornstein, Dr. Aviv Regev, Barbara Schädler, Boris L. Zaïtra
Rada nadzorcza
Dr. Severin Schwan, André Hoffmann, Anita Hauser, Dr. Claudia Süssmuth Dyckerhoff, Dr. Patrick Frost, Prof. Dr. Richard Lifton, Dr. Mark Schneider, Dr. Jemilah Mahmood, Prof. Dr. Akiko Iwasaki, Dr. Jörg Duschmalé
 

Dane firmy

Nazwa: Roche Holding
Adres: Grenzacherstraße 124,CH-4070 Basel
Telefon: +41-61-688-1111
Fax: -
E-mail: basel.webmaster@roche.com
Internet: www.roche.com
Przemysł: Służba zdrowia
Sektor: Przemysł Farmaceutyczny
Podsektor: Przemysł Farmaceutyczny
Koniec roku finansowego: 31.12
Free float: 88,00%
Data IPO: 03.04.1995

Relacje inwestorskie

Nazwa: Bruno Eschli
Telefon: +41 (61) 687 5284
Fax: +41 (61) 691 0014
E-mail: bruno.eschli@roche.com

Główni akcjonariusze

Group with pooled rights
 
64,97%
Inne
 
27,45%
Maja Oeri
 
7,58%